GlaucoPharm

Kador, Riau, Indonesia

http://abital.co.il/portfolio-item/glaucopharm-p/

Company profile

GlaucoPharm company profile

GlaucoPharm is developing TG-46, a novel topical treatment for glaucoma. TG-46 is useful for the treatment of diseases modulated by the Pyrimidinergic receptor P2Y6, such lowering intraocular pressure (IOP) and there by Glaucoma. The P2Y6 receptor has been identified in Trabecular Meshwork cells (TM), an area of tissue in the eye that is responsible for draining the aqueous humor. TG-46 shows evidence of a novel mechanism of action, potential alternative to first line drugs, It binds tightly and selectively to P2Y6R. TG-46 reduces IOP by 45%, compared to the 25-35% of current drugs in the market. It is highly chemically..... For more information, log in to dureach.com to view the full company profile.

Business identity

Website: http://abital.co.il/portfolio-item/glaucopharm-p/
Contact email: [email protected]
Operating status: Active
Company type: For Profit
Employee range: 00001-00010 employees
Founded: 2013-01-01

Headquarters

Headquarters: Kador, Riau, Indonesia
Country code: ID
Continent: Asia

Capital profile

Funding and company signals

Founders: 1

Categories and groups

Biotechnology Medical Biotechnology Health Care Science and Engineering

Founders and investors

Founders

Santiago Ini

People at this company

Preview only. Contact details are available after you sign in.

Contact information and company affiliations may no longer be accurate. Verify details before reaching out.

Shipment data

Explore detailed shipment data

Shipment records and coverage can change as the dataset is updated.